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Background: A substantial fraction of familial colorectal cancer (CRC) and polyposis heritability remains unexplained. This study
aimed to identify predisposing loci in patients with these disorders.
Methods: Homozygosity mapping was performed using 222 563 SNPs in 302 index patients with various colorectal neoplasms and 3367
controls. Linkage analysis, exome and whole-genome sequencing were performed in a family affected by microsatellite stable CRCs.
Candidate variants were genotyped in 10 554 cases and 21 480 controls. Gene expression was assessed at the mRNA and protein level.
Results: Homozygosity mapping revealed a disease-associated region at 1q32.3 which was part of the linkage region 1q32.2–42.2
identified in the CRC family. This includes a region previously associated with risk of CRC. Sequencing identified the
p.Asp1432Glu variant in the MIA3 gene (known as TANGO1 or TANGO) and 472 additional rare, shared variants within the linkage
region. In both cases and controls the population frequency was 0.02% for this MIA3 variant. The MIA3 mutant allele showed
predominant mRNA expression in normal, cancer and precancerous tissues. Furthermore, immunohistochemistry revealed
increased expression of MIA3 in adenomatous tissues.
Conclusions: Taken together, our two independent strategies associate genetic variations in chromosome 1q loci and
predisposition to familial CRC and polyps, which warrants further investigation.
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Family history is a major risk factor in colorectal cancer (CRC)
aetiology. Familial aggregation of disease is observed in up to 25%
of the cases and estimates from twin studies indicate that inherited
genetic factors contribute to the development of CRCs in
approximately 15% of cases (Kerber et al, 2005; Mucci et al,
2016). It is generally accepted that a substantial proportion of CRC
incidence is due to predisposition to non-malignant CRC lesions
(e.g., adenomas, serrated lesions). Indeed, first-degree relatives of
patients with colorectal adenomas have an increased risk of
developing colorectal adenocarcinomas (Johns and Houlston, 2001;
Tuohy et al, 2014).
Only up to 14% of CRC predisposition can be attributed to the
known Mendelian-inherited syndromes and common gene var-
iants, suggesting that a substantial fraction of this heritability
remains unexplained (Aaltonen et al, 2007; Dunlop et al, 2013; Jiao
et al, 2014). In support of this, linkage studies in CRC families have
identified disease-associated chromosomal areas where predispos-
ing genes have not yet been identified (Wiesner et al, 2003; Kemp
et al, 2006; Neklason et al, 2008; Middeldorp et al, 2010). Similarly,
some regions, such as chromosome 1q41 (rs6691170, rs6687758
and rs11118883), identified in genome-wide association studies
(GWAS) still have not led to the identification of functional CRC
variants (Houlston et al, 2010; Spain et al, 2012; Zhang et al, 2014).
Furthermore, one study measuring runs of homozygosity in search
for recessive disease-causing loci, did not identify novel CRC
predisposing loci (Spain et al, 2009). In recent years, advances in
sequencing technologies have made it possible to identify germline
susceptibility loci that were previously not encountered in linkage
and association studies. For example, using a combination of
sequencing and linkage studies germline mutations were identified
in two DNA-polymerase genes (POLE and POLD1) (Palles et al,
2013).
In this study, we searched for germline variants involved in
colorectal neoplasm susceptibility using two independent genomic
strategies. Homozygosity mapping analysis was conducted in a
cohort of 302 index patients with various colorectal neoplasms,
ranging from few to hundreds of polyps and 3367 controls. In
parallel, a combination of linkage analysis and sequencing was
performed in individuals from a large family with an extensive
history of microsatellite stable CRC. Both strategies identified an
association of chromosome 1q loci with these diseases.
MATERIALS AND METHODS
Ethics. The study was approved by the Medical Ethical Committee
of the Leiden University Medical Center, Leiden, The Netherlands
(protocol P01–019). Informed consent was given for further
research at initial blood withdrawal for the homozygosity mapping
cohort, family 68 and the MIA3 genotyping cohorts. Anonymised
tissue samples were handled according to the medical ethical
guidelines described in the Code Proper Secondary Use of Human
Tissue established by the Dutch Federation of Medical Sciences
(https://www.federa.org/) and informed consent was waived for the
use of these samples by the Medical Ethical Committee (protocol
P01–019).
CytoSNP array genotyping. A cohort of patients with multiple
adenomas, previously described by (Hes et al, 2014), and patients
with o10 adenomas or a phenotype with predominantly serrated
lesions, were included in this study. The clinical characteristics of
the cohort are presented in Supplementary Table 1. All cases were
negative for known pathogenic variants in the MMR genes, APC
(including mosaic APC), POLE, POLD1, MUTYH or NTHL1. A
total of 343 cases were genotyped using the Illumina HumanCy-
toSNP-12 v2.0 or v2.1 BeadChips (Illumina Inc., San Diego, CA,
USA). For controls we used genotypes of 3367 individuals from the
LifeLines cohort study (Stolk et al, 2008; Dolmans et al, 2011). A
total of 222 563 SNPs in 302 cases and 3367 controls passed quality
control. The quality control procedure is described in
Supplementary Methods.
Homozygosity mapping. SNP selection and homozygosity map-
ping analysis is described in Supplementary Methods. In total
78 582 SNPs were included in the analysis. Runs of homozygosity
were compared between cases and controls using the Fisher‘s exact
test (Po1.2 10 6).
Genome-wide association study. A quantile–quantile (Q–Q) plot
of the observed and expected P-values indicated differential
genotyping between cases and controls. A genomic inflation factor
(based on median w2) l¼ 1.23378 was applied to correct for the
population bias between cases and controls. Genotype prevalence
of 222 563 SNPs was compared between cases and controls using a
w2 allelic test with 1 degree of freedom. Odds ratio and its 95%
confidence interval was also computed. Multiple test correction
was done using false discovery rate estimation (Benjamini and
Yekutieli, 2001).
Family 68 characterisation. Clinicopathological data of family 68
family members were obtained from the national registry of The
Netherlands Foundation for the Detection of Hereditary Tumours
(http://www.stoet.nl) and are shown in Supplementary Table 2.
Peripheral blood was collected from 16 members of family 68.
DNA was extracted using standard techniques. Index patient 68-01
had been screened and was found to be negative for known
pathogenic variants in the MMR genes, APC, POLE, POLD1,
MUTYH and NTHL1.
Linkage analysis. Fifteen family members of family 68, including
one unaffected spouse, were genotyped using the GeneChip
Mapping 10 K Xba 142 array (Affymetrix Inc., Santa Clara, CA,
USA). Data was previously described (Middeldorp et al, 2010).
SNPs with a call rate below 90% were excluded from further
analysis. A total of 9131 SNPs had a valid annotation. Genotypes
incompatible with the family relations were removed using
pedcheck. Non-parametric linkage analysis was performed with
MERLIN (Abecasis et al, 2002) using S-all scoring (Whittemore
and Halpern, 1994) with the exponential model (Kong and Cox,
1997). Patients diagnosed with CRC before 60 years or with
colorectal polyps before 55 years were considered affected. Other
family members were classified as unaffected.
Exome and whole-genome sequencing. Exome sequencing was
performed on family 68 DNA samples (68-01, 68-08, 68-11, 68-15
and 68-17) using HiSeq (Illumina) or Complete Genomics
(Complete Genomics Inc., Mountain View, CA, USA) sequencing
technology (Carnevali et al, 2012) as described in Supplementary
Methods. Samples (68-07, 68-11 and 68-15) were sent to Macrogen
(Macrogen Europe, Amsterdam, The Netherlands) for whole-
genome sequencing (Supplementary Methods). Variants with a
population frequency40.01 (in 1000Genomes, ExAC, ESP or
GoNL databases) were excluded. For the analysis of the exome
sequencing data, we selected variants predicted to be coding or
affecting splice-sites. In the whole-genome analysis, we prioritised
the non-coding variants which were present within the linkage
peak based on regions under strong negative selection, as
previously described (Khurana et al, 2013).
MIA3 p.Arg1432Glu genotyping. The MIA3 c.4296T4A,
p.Asp1432Glu variant was validated by standard bidirectional
Sanger sequencing. A KASPar assay was designed for the MIA3
p.Asp1432Glu variant by KBioscience (LGC Genomics, Hoddes-
don, UK). Leucocyte or normal colon tissue derived DNA was
screened of 1477 CRC patients, 445 polyposis patients and 1604
population-based controls (anonymous blood donors) from The
Netherlands and 1098 CRC patients and 1459 healthy controls
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from the Czech Republic (Pardini et al, 2013). All carriers were
validated by Sanger sequencing and the existence of a common
ancestor was excluded using STR profiling (Supplementary
Methods). Additionally, MIA3 genotypes were extracted from a
European cohort of 7534 CRC patients and 18 417 healthy controls
that were genotyped using OmniExpressExome BeadChip 8v1.1 or
8v1.20 (Illumina) (Timofeeva et al, 2015).
Somatic MIA3 mutation analysis. Tumour DNA of 47 micro-
satellite stable CRCs was screened for somatic MIA3 mutations
(Supplementary Table 3). Paired tumour-normal DNA samples of
MIA3 p.Asp1432Glu carriers (68-1 and both carriers identified
with screening) were screened for second hits in the MIA3 gene.
Sequencing was performed with a custom multiplex PCR on the
Ion Torrent Personal Genome Machine sequencer (Life Technol-
ogies, Grand Island, NY, USA) as described in Supplementary
Methods. Synonymous and intronic variants were excluded as well
as variants present in population frequency databases (in
1000Genomes, ExAC, ESP or GoNL).
For comparison, the somatic mutation data from 915 colorectal
adenocarcinoma exomes (Muzny et al, 2012; Seshagiri et al, 2012;
Giannakis et al, 2016) was retrieved from The cancer genome atlas
(TCGA) using cBioPortal (Cerami et al, 2012; Gao et al, 2013).
Quantitative real-time reverse transcriptase PCR. mRNA was
isolated from fresh frozen tissue samples of 18 normal tissues, 32
colorectal adenomas and 18 colorectal adenocarcinomas
(Supplementary Table 4). mRNA isolation and quantitative real-
time reverse transcriptase PCR were performed as previously
described (Lips et al, 2008; van Roon et al, 2013). MIA3 mRNA
expression of the full-length isoform (primer sequences available
upon request) was normalised to housekeeping genes CPSF6 and
HNRNPM (van Roon et al, 2013). Group differences were tested
with one-way ANOVA.
Allele-specific expression. Formalin-fixed, paraffin-embedded
tissue blocks of MIA3 p.Asp1432Glu carriers were collected
(caecum carcinoma and normal tissue; two serrated lesions, two
adenomas and normal colon tissue). Total nucleic acid was
extracted using the Tissue Preparation System (Siemens Healthcare
Diagnostics, Tarrytown, NY, USA) (van Eijk et al, 2013). Nucleic
acid was treated with DNaseI (Fermentas, Thermo Fisher
Scientific, Waltham, MA, USA) and converted into cDNA using
the High-Capacity cDNA reverse transcription kit (Applied
Biosystems, Foster City, CA, USA). Allele-specific expression
analysis of the MIA3 variant was performed using 2 ml 25x diluted
cDNA as template for the KASPar assay. Paired DNA was analysed
to determine baseline amplification differences between the two
alleles. Using the Cq values obtained for both alleles, the allelic
dosage was calculated similarly to the Pfaffl method for relative
gene expression (Pfaffl, 2001).
Immunohistochemistry. Formalin-fixed, paraffin-embedded tis-
sues blocks were available of 82 patients from the FACTS study
(Hennink et al, 2015) (which included 18 serrated lesions and 97
adenomas with low-grade dysplasia) and a series of 15 anonymous
colorectal adenocarcinomas. Formalin-fixed, paraffin-embedded
and fresh frozen tissue sections of MIA3 p.Asp1432Glu carriers
were stained. MIA3 immunohistochemistry was performed as
described in Supplementary Methods. The intensity of MIA3
cytoplasmic staining was classified as negative-weak or moderate-
strong. Normal mucosa was analysed when present in the tissue
sections. MIA3 gradient expression was scored: maximal staining
at the base of the crypts and decreasing towards the lumen (top-
down), maximal staining at the lumen and decreasing toward the
base of the crypts (down-top) or homogeneous staining across
lumen and crypt (no gradient). Differences between tissue types
were compared using a Fisher’s exact test.
RESULTS
Genotyping and homozygosity mapping in colorectal neoplasm
cases. We genotyped germline DNA samples from index patients
affected with colorectal neoplasms ranging from few to hundreds
of polyps (polyposis), with and without CRC. After sample and
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Figure 1. Overrepresentation of runs of homozygosity located on chromosome 1q32.3 in patients with colorectal neoplasms. (A) Frequency of
the runs of homozygosity on chromosome 1; cases (blue) and controls (pink). Overrepresented homozygosity in cases is indicated with a red box.
(B) Overlapping runs of homozygosity of six cases (blue bars) at chromosomal locus 1q32.3.
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genotypes for 222 563 SNPs from 302 cases and 3367 controls were
included. We removed SNPs with a MAFo0.05 or SNPs in linkage
disequilibrium, resulting in 80 907 remaining SNPs. Using PLINK,
we searched for runs of homozygosity containing X15 homo-
zygous SNPs and spanning a region of at least 1.5 Mb. A total of
40 849 runs of homozygosity were identified in the cases and
controls, with an average size of 2.73 Mb. Per individual a similar
number of runs of homozygosity (10.4 vs 11.2) and a cumulative
length of homozygosity (average 28.7 vs 30.5 Mb), were observed in
cases and controls, respectively. On chromosome region 1q32.3,
runs of homozygosity were overrepresented in cases compared to
controls (2.0 vs 0.1%; P¼ 0.0001), although not reaching genome-
wide significance after correction for multiple testing (Figure 1).
This 1 Mb region of homozygosity (chr1:211 265 284–212 357 017),
bounded by SNPs rs1338348 and rs11119874, was identified in six
patients diagnosed with multiple polyps before 56 years of age; five
out of six had 410 neoplastic lesions (Supplementary Table 5).
This region contains 10 coding genes and 2 small non-coding
RNAs (UCSC gene database). No individual SNPs, including
chromosome 1q SNPs rs11118883 and rs6687758, reached global
significance in a GWAS analysis utilising the same SNPs.
Clinical characterisation and linkage analysis in family 68. In
parallel to the homozygosity mapping analysis we performed
linkage analysis in a family not included in the homozygosity
mapping cohort. Updated clinical follow-up information war-
ranted the reanalysis of a previously described Amsterdam criteria
I fulfilling family affected with microsatellite stable CRCs without a
known causative mutation (Middeldorp et al, 2010). Fifteen
individuals of this family (68-01 until 68-15) were genotyped
using Affymetrix 10 K SNP arrays (Figure 2). For non-parametric
linkage analysis only individuals presenting with early-onset
colorectal neoplasms (X1 adenoma before 55 years and/or CRC
before 60 years) were considered affected. All affected family
members developed less than 10 polyps. The clinical presentation
of the late-onset patients included the diagnosis of CRC in an
elderly patient at 88 years of age (68-13) and the identification of
1–2 adenomas during periodic colonoscopy screenings in three
relatives, aged 56–60 years (68-02, 68-06 and 68-09). Furthermore,
the linkage analysis included one family member without a history
of polyps or cancer at 59 years of age and one unaffected spouse.
We identified a region of suggested linkage (logarithm of odds
(LOD)42.5; maximum LOD score¼ 2.75) on chromosome
1q32.2-q42.2 (Figure 3). No additional linkage regions were
identified (LOD40.8). The linkage region spans 21.1 Mb
(chr1:210 940 342–232 031 815) and overlaps with the region of
homozygosity described above, located on chromosome 1q32.3.
The whole region is predicted to contain 137 coding genes and 48
small non-coding RNAs (UCSC gene database).
Germline sequencing in family 68. To further investigate the
chr1q loci identified with homozygosity mapping and linkage
analysis, we focussed on the largest region, the linkage region in
family 68. In search of disease-associated variants, exome
sequencing was performed on DNA from five affected family
members (68-1, 68-8, 68-11, 68-15 and 68-17). Exonic or predicted
splice-site variants with a maximum population frequency below
0.01 were selected. Three variants were shared amongst these five
individuals (Table 1), of which only one was located within the
linkage peak; the c.4296T4A, p.Asp1432Glu variant in Melanoma
Inhibitory Activity protein 3 gene (MIA3, also known as TANGO1
or TANGO). Additional variants identified within the linkage peak
were not shared between the individuals (Supplementary Table 6).
Segregation analysis, using Sanger sequencing, showed that all
family members presenting with early-onset colorectal neoplasms
were carriers of the MIA3 p.Asp1432Glu variant, whereas one
unaffected relative (68-04), one patient with a single polyp at 60
years of age (68-9) and one unaffected spouse (68-14) were non-
carriers. The MIA3 variant was present in three late-onset patients
(68-02, 68-06, 68-13).
To investigate the presence of variants in non-coding regions on
chromosome 1q32.2-q42.2, whole-genome sequencing was per-
formed in three family members (68-7, 68-11 and 68-15). Of the
known CRC risk alleles located on chromosome 1q (rs6691170,
rs6687758 or rs11118883) all individuals carried the non-risk
alleles with one exception, individual 68-11 was heterozygous for
the rs6691170 allele. Next, heterozygous variants shared amongst
all three individuals and with a maximum population frequency of








Figure 2. Pedigree of family 68. Filled symbol, colorectal cancer. Filled quarter, X1 adenoma. Black, early-onset colorectal neoplasms
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Figure 3. Non-parametric linkage analysis in family 68. Logarithm of
odds scores of chromosome 1 (in centiMorgan) of the non-parametric
linkage analysis of 15 individuals using the exponential model.
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473 variants were identified, 51% were single nucleotide variants
and 49% insertion or deletions (81% in genetic repeat sequences).
In total 33 variants were located within the homozygosity mapping
region located on chromosome 1q32.3. Within 1 Mb of the MIA3
gene 45 variants were identified (chr1:221 791 444–223 841 354). In
addition, one exonic variant was found (OBSCN: NM_001098623
c.4523T4A, p.Val1508Asp), which was not covered in the exome
sequencing. Subsequently, we investigated variants located in
regions under strong negative selection, i.e. non-coding regions
harbouring an increased fraction of rare variants comparable to the
coding region, which are subdivided into ultrasensitive (e.g., BRF2-
binding site) and sensitive regions (binding sites of some
chromatin and general transcription factors). One variant,
rs529680452, was identified in a sensitive non-coding element; in
the binding domain of histone acetyltransferase KAT2A located in
the 50 untranslated region of the DTL gene (Supplementary
Table 7). Thus, the MIA3 p.Asp1432Glu variant seemed the most
promising candidate for the colorectal neoplasm predisposition in
this family and was selected for further investigation.
Prevalence of the MIA3 p.Asp1432Glu variant. The MIA3
p.Asp1432Glu variant is present at low frequencies in public
genotype databases; 0.01% the in ESP database (1/5997), 0.05% in
the ExAC database (55/59 662) and 0.1% in the Genome of The
Netherlands project (1/498). We performed or collected additional
genotyping data of 10 554 cases and 21 480 controls. Analysis over
all cohorts revealed an allele frequency of 0.02% in both cases and
controls; separate frequencies per cohort are shown in
Supplementary Figure 1. KASPar genotyping of the Dutch CRC
cohort identified two additional carriers of the p.Asp1432Glu
variant. No carriers were found in the cases used for homozygosity
mapping.
Clinical characterisation MIA3 p.Asp1432Glu carriers. STR
profiling provided no evidence of a recent common ancestor
between the 68-01 and the other two carriers. One patient has a
positive family history of both CRC and adenomas and has a
confirmed germline deletion in MSH2. This patient developed a
microsatellite instability-high (MSI-H) caecum tumour at age 44.
Table 1. Variants present in all five affected family members identified with exome sequencing
Gene Chromosome band GenBank accession number mRNA change Protein change Reference SNP cluster ID
MIA3 1q41 NM_198551 c.4296 T4A p.Asp1432Glu rs199885504
SIPA1L2 1q42.2 NM_020808 c.4966 G4A p.Gly1656Arg —























































































































































































Figure 4. mRNA and protein expression of MIA3 in colon tissues. (A) mRNA expression of MIA3 (relative to housekeeping genes CPSF6 and
HNRNPM) in colonic tissues. (B) The p.Asp1432Glu variant was higher expression than the wild-type allele in both normal colonic tissue and colon
lesions. (C) A significant increase in protein expression is observed in adenomas and a significant decrease in carcinomas, compared to normal
colorectal tissue sections. (D) Gradient expression of MIA3 protein was more frequent in serrated lesions and adenomas compared to carcinomas.
Serrated lesions show higher expression basally, while adenomas had higher expression on the luminal side of the polyp. *Pp0.05, **Pp0.01.
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The other patient had no germline mutations in CRC genes and no
known family history of disease. The patient developed micro-
satellite stable rectal cancer at 40 years and underwent a
hemicolectomy of the left-sided colon and rectum at age 56 after
developing 420 polyps (both adenomas and serrated lesions).
MIA3 somatic mutations. We performed targeted somatic
mutation screening of MIA3 in tumour DNA from p.Asp1432Glu
MIA3 carriers. In the MSI-H tumour a somatic mutation was
present (c.55701G4A, p.Gly1857Asp). No second hits in MIA3
were detected in the other tumour samples. In addition, MIA3 was
screened in 47 familial microsatellite stable CRCs. Somatic non-
synonymous MIA3 mutations were observed in 6.4% of the
tumours (Supplementary Table 8). Our findings are in line with the
somatic mutation frequency of 4.5% in 915 colorectal adenocarci-
nomas from TCGA.
MIA3 mRNA and allele-specific expression. Using quantitative
real-time PCR, MIA3 expression was quantified in mRNA isolated
from normal tissues, colorectal adenomas and colorectal adeno-
carcinomas. High variability in expression was observed within
each group and showed no significant difference in expression
between the groups (P¼ 0.684; Figure 4A). We investigated the
allele-specific expression of the MIA3 variant in tissues derived
from p.Asp1432Glu MIA3 carriers. mRNA expression of the
mutant allele was three times higher in normal tissue samples and
more than four times higher in colorectal neoplasms (Figure 4B).
MIA3 protein expression. To better understand the potential role
of MIA3, we examined MIA3 expression in precancerous color-
ectal lesions and colorectal carcinoma tissue sections. A general
decrease in MIA3 expression was observed in adenocarcinomas
compared to normal mucosa (13 vs 46% moderate-strong staining;
P¼ 0.04; Figure 4C). Notably, higher MIA3 expression was seen in
colorectal polyps, 67% of serrated lesions and 70% of adenomas
showed moderate-strong staining (P¼ 0.18, P¼ 0.006, respectively,
compared to normal mucosa). A gradient in MIA3 expression was
observed in polyps (representative tissue sections in Supplementary
Figure 2), while no gradient was present in normal mucosa. In
serrated lesions MIA3 expression was highest at the base of the
crypts and decreased towards the lumen (down-top gradient),
while in adenomas the inverse gradient was observed (top-down
gradient) (Figure 4D).
In tissue sections from p.Asp1432Glu carriers, the MIA3
expression was highly variable but not distinctive from non-
carriers. These results mainly show high inter- and intra-patient
heterogeneity, independent of the MIA3 p.Asp1432Glu germline
variant.
DISCUSSION
To date, genetic association studies have reported many SNPs
associated with either CRC or multiple adenoma susceptibility,
including rs6691170, rs6687758, rs11118883 located on chromo-
some region 1q41 (Spain et al, 2012; Theodoratou et al, 2012;
Montazeri et al, 2016). In contrast, homozygosity mapping studies
have been less successful in the identification of predisposition loci
in CRC and other types of cancers, indicating that recessive
syndromes might be less frequent in genetic predisposition to
cancer (Spain et al, 2009; Enciso-Mora et al, 2010; Hosking et al,
2010; Sud et al, 2015). In this study we found a recurrent region of
homozygosity located on chromosome 1q32.3 (chr1:211 265 284–
212 357 017) in patients with a mixed early-onset colorectal
neoplasm phenotype. For this study we included patients with a
large spectrum of cancerous and precancerous colorectal lesions, as
known hereditary CRC syndromes also have a highly variable
clinical presentation. None of the runs of homozygosity or single
SNPs in our GWAS analysis reached significance with the genome-
wide thresholds, which mainly reflects a lack of power and
underscores the need for larger sample sizes. In a highly
overlapping cohort, two variants significantly associated with
disease, rs3802842 (chr11q23) and rs4779584 (chr15q13), however,
only 16 SNPs were tested (Hes et al, 2014). Hence, despite
adjustment for multiple testing, the association between early-onset
colorectal neoplasm risk and chromosome 1q32.3 in susceptibility
to multiple colorectal neoplasms warrants further investigation.
Furthermore, a linkage peak was identified in 15 individuals
from a large family with an extensive history of microsatellite
stable CRC and polyps located on chromosome 1q32.2–42.2. As an
individual finding the identification of the linkage region in a
single family or the region of homozygosity in the colorectal
neoplasm cohort might not provide compelling evidence for the
involvement of this region. However, together the linkage region,
the 21.1 Mb region of homozygosity and previously described
predisposing and protective CRC risk alleles (Spain et al, 2012)
located in a highly overlapping region are suggestive of a broad-
based association of chr1q and CRC predisposition. Therefore we
decided to further investigate this association by focussing on the
broadest, most inclusive region, which was the linkage region
identified in family 68.
Although the family presented with a dominant pattern of
inheritance, we proceeded with the screening of rare genetics
variants in family 68 looking into heterozygous, homozygous and
compound heterozygous variants within the linkage region. Based
on exome sequencing results, the most likely candidate variant
for predisposition was the heterozygous MIA3 c.4296T4A;
p.Asp1432Glu variant. MIA3 (also known as TANGO or
TANGO1) is a cargo receptor localised to the endoplasmic
reticulum and facilitates the trafficking of collagens to the Golgi
apparatus (Wilson et al, 2011; Ishikawa et al, 2016). The
p.Asp1432 amino acid is located in the cytoplasm in the first
out of two coiled-coiled domains of MIA3 (amino acids 1211–
1440) (Saito et al, 2011). This region may interact with still
unidentified intermediates of this transport carrier complex and
we hypothesised that missense variants may stabilise or
destabilise these protein interactions. MIA3 was shown to
promote angiogenesis and lymphangiogenesis in oral squamous
cell carcinoma (Sasahira et al, 2014). Furthermore, patients with
MIA3-positive squamous cell carcinomas have a significantly
shorter disease-free survival than patients without MIA3 expres-
sion (Sasahira et al, 2016). However, downregulation was
observed in melanomas, hepatocellular and colon carcinomas
(Arndt and Bosserhoff, 2006; 2007; Sasahira et al, 2014). To our
knowledge we are the first to describe an increased protein
expression in colorectal adenomas, which might indicate a
tumourigenic role of MIA3 in the development of these
precancerous lesions. In addition, our data showed a tissue
gradient in adenomas and the inverse gradient in serrated lesions,
possibly correlated to the proliferating cells in these polyps. At
the mRNA level no differences were observed between adenomas,
carcinomas and normal colon tissue.
No differential protein expression was observed in tissue from
carriers and non-carriers of the MIA3 p.Asp1432Glu variant,
although only a limited number of tissue blocks were available
from carriers. In addition, genotyping data did not support the
involvement of this MIA3 variant in CRC predisposition, based on
similar allele frequencies in cases and controls. The observed allelic
imbalance of the p.Asp1432Glu MIA3 allele in carriers could
possibly be explained by the presence of regulatory variants in
linkage, leading to the up-regulation of the mutant allele compared
to the wild-type allele in these individuals.
To investigate the possibility of non-coding variants underlying
CRC predisposition in family 68, whole-genome sequencing was
performed. We focussed on heterozygous variants within the
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linkage region due to the predicted dominant pattern of
inheritance in this family. In total 473 heterozygous, shared, rare
variants were identified. One additional coding variant, OBSCN
p.Arg4213His, was identified in a region not covered by the exome
sequencing analysis. The OBSCN gene codes for obscurins, giant
cytoskeletal Rho-guanine nucleotide exchange factor proteins, that
interact with cytoskeletal calmodulin and titin (Young et al, 2001).
The OBSCN gene is frequently mutated in CRC and other cancers,
however, to date, research lacks to support an association of
germline variants and increased cancer risks (Sjoblom et al, 2006;
Balakrishnan et al, 2007; Huhn et al, 2014).
As no regulatory elements of MIA3 have been described, we
selected variant located between 1 Mb up- and down-stream of
the MIA3 gene and identified 45 variants (Sotelo et al, 2010).
None of these variant were located in regions under strong
negative selection (Khurana et al, 2013), such as regions
important for transcription factor binding, and therefore
additional research is needed to investigate the effect of these
45 variants on MIA3 transcription. Of the 473 variants only one
was present in a region under strong negative selection, a rare
variant (rs529680452) in the binding domain of histone
acetyltransferase KAT2A located in the 50 untranslated region
of the DTL gene. Denticleless E3 ubiquitin protein ligase
homologue, encoded by the DTL gene, is upregulated in various
cancers, including CRC, and it is reported to play a crucial role in
carcinogenesis (Cheung et al, 2001; Pan et al, 2006; Ueki et al,
2008; Baraniskin et al, 2012; Kobayashi et al, 2015). Variants in
transcription factor binding sites have previously been associated
with an increased risk of cancer, the most well studied are long-
range enhancers of MYC (Ahmadiyeh et al, 2010; Sotelo et al,
2010). The DTL variant is one out of 33 non-coding variants
located in the 1 Mb region identified with homozygosity mapping
analysis on chromosome 1q32.3, which are also interesting
candidates and warrant for further investigation.
Taken together, this study identifies, with two independent
strategies, a genomic region on chromosome 1q which is associated
with the predisposition to CRC and multiple polyps. Several other
studies have pinpointed this region in CRC genetic association
studies. Novel comprehensive approaches are required for the
identification of functional variants predisposing to CRC, possibly
affecting regulatory elements or non-coding RNAs.
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d’Ajuts Universitaris i de Recerca (Generalitat de Catalunya,
2014SGR255). We are sincerely grateful to the Biobank of
Hospital Clı́nic-IDIBAPS for technical help. The work was
carried out in part at the Esther Koplowitz Centre and FPGMX.
CIBERehd and CIBERER are funded by the Instituto de Salud
Carlos III. We acknowledge core funding to the Wellcome Trust
Centre for Human Genetics from the Wellcome Trust (090532/Z/
09/Z) and the Oxford NIHR Biomedical Research Centre. We
thank Rashmi Dibipsersat, Nesli Ozcelik, Melanie Schrumpf and
Brendy van den Akker for their technical support.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Aaltonen L, Johns L, Jarvinen H, Mecklin JP, Houlston R (2007) Explaining
the familial colorectal cancer risk associated with mismatch repair
(MMR)-deficient and MMR-stable tumors. Clin Cancer Res 13(1):
356–361.
Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin–rapid
analysis of dense genetic maps using sparse gene flow trees. Nat Genet
30(1): 97–101.
Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, Almendro V,
He HH, Brown M, Liu XS, Davis M, Caswell JL, Beckwith CA, Hills A,
Macconaill L, Coetzee GA, Regan MM, Freedman ML (2010) 8q24
prostate, breast, and colon cancer risk loci show tissue-specific long-range
interaction with MYC. Proc Natl Acad Sci USA 107(21): 9742–9746.
Arndt S, Bosserhoff AK (2006) TANGO is a tumor suppressor of malignant
melanoma. Int J Cancer 119(12): 2812–2820.
Arndt S, Bosserhoff AK (2007) Reduced expression of TANGO in colon and
hepatocellular carcinomas. Oncol Rep 18(4): 885–891.
Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A,
van Tilborg AA, Leenstra S, Zanon C, Bardelli A (2007) Novel somatic and
germline mutations in cancer candidate genes in glioblastoma, melanoma,
and pancreatic carcinoma. Cancer Res 67(8): 3545–3550.
Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zollner H, Munding J,
Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W,
Hahn SA (2012) MiR-30a-5p suppresses tumor growth in colon
carcinoma by targeting DTL. Carcinogenesis 33(4): 732–739.
Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in
multiple testing under dependency. Ann Stat 29(4): 1165–1188.
Carnevali P, Baccash J, Halpern AL, Nazarenko I, Nilsen GB, Pant KP,
Ebert JC, Brownley A, Morenzoni M, Karpinchyk V, Martin B,
Ballinger DG, Drmanac R (2012) Computational techniques for human
genome resequencing using mated gapped reads. J Comput Biol 19(3):
279–292.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A,
Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP,
Sander C, Schultz N (2012) The cBio cancer genomics portal: an open
platform for exploring multidimensional cancer genomics data. Cancer
Disc 2(5): 401–404.
Cheung WM, Chu AH, Chu PW, Ip NY (2001) Cloning and expression of a
novel nuclear matrix-associated protein that is regulated during the
retinoic acid-induced neuronal differentiation. J Biol Chem 276(20):
17083–17091.
Dolmans GH, Werker PM, Hennies HC, Furniss D, Festen EA, Franke L,
Becker K, van der Vlies P, Wolffenbuttel BH, Tinschert S, Toliat MR,
Nothnagel M, Franke A, Klopp N, Wichmann HE, Nurnberg P, Giele H,
Ophoff RA, Wijmenga C (2011) Wnt signaling and Dupuytren’s disease.
N Engl J Med 365(4): 307–317.
Dunlop MG, Tenesa A, Farrington SM, Ballereau S, Brewster DH, Koessler T,
Pharoah P, Schafmayer C, Hampe J, Volzke H, Chang-Claude J,
Hoffmeister M, Brenner H, von Holst S, Picelli S, Lindblom A,
Jenkins MA, Hopper JL, Casey G, Duggan D, Newcomb PA, Abuli A,
Bessa X, Ruiz-Ponte C, Castellvi-Bel S, Niittymaki I, Tuupanen S,
Karhu A, Aaltonen L, Zanke B, Hudson T, Gallinger S, Barclay E,
Martin L, Gorman M, Carvajal-Carmona L, Walther A, Kerr D, Lubbe S,
Broderick P, Chandler I, Pittman A, Penegar S, Campbell H, Tomlinson I,
Houlston RS (2013) Cumulative impact of common genetic variants and
other risk factors on colorectal cancer risk in 42,103 individuals. Gut
62(6): 871–881.
Enciso-Mora V, Hosking FJ, Houlston RS (2010) Risk of breast and prostate
cancer is not associated with increased homozygosity in outbred
populations. Eur J Hum Genet 18(8): 909–914.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y,
Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013)
Integrative analysis of complex cancer genomics and clinical profiles using
the cBioPortal. Sci Signal 6(269): pl1.
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S,
Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C,
Chromosome 1q loci in familial colorectal cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com | DOI:10.1038/bjc.2017.240 7
Rosenberg M, Mima K, Inamura K, Nosho K, Nowak JA, Lawrence MS,
Giovannucci EL, Chan AT, Ng K, Meyerhardt JA, Van Allen EM, Getz G,
Gabriel SB, Lander ES, Wu CJ, Fuchs CS, Ogino S, Garraway LA (2016)
Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell
Rep 17(4): 1206.
Hennink SD, van der Meulen-de Jong AE, Wolterbeek R, Crobach AS,
Becx MC, Crobach WF, van Haastert M, Ten Hove WR, Kleibeuker JH,
Meijssen MA, Nagengast FM, Rijk MC, Salemans JM, Stronkhorst A,
Tuynman HA, Vecht J, Verhulst ML, de Vos Tot Nederveen Cappel WH,
Walinga H, Weinhardt OK, Westerveld D, Witte AM, Wolters HJ, Cats A,
Veenendaal RA, Morreau H, Vasen HF (2015) Randomized comparison of
surveillance intervals in familial colorectal cancer. J Clin Oncol 33(35):
4188–4193.
Hes FJ, Ruano D, Nieuwenhuis M, Tops CM, Schrumpf M, Nielsen M,
Huijts PE, Wijnen JT, Wagner A, Gomez Garcia EB, Sijmons RH,
Menko FH, Letteboer TG, Hoogerbrugge N, Harryvan J, Kampman E,
Morreau H, Vasen HF, van Wezel T (2014) Colorectal cancer risk variants
on 11q23 and 15q13 are associated with unexplained adenomatous
polyposis. J Med Genet 51(1): 55–60.
Hosking FJ, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E,
Irving JA, Allan JM, Taylor M, Tomlinson IP, Greaves M, Houlston RS
(2010) Genome-wide homozygosity signatures and childhood acute
lymphoblastic leukemia risk. Blood 115(22): 4472–4477.
Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K,
Spain SL, Broderick P, Domingo E, Farrington S, Prendergast JG,
Pittman AM, Theodoratou E, Smith CG, Olver B, Walther A,
Barnetson RA, Churchman M, Jaeger EE, Penegar S, Barclay E, Martin L,
Gorman M, Mager R, Johnstone E, Midgley R, Niittymaki I, Tuupanen S,
Colley J, Idziaszczyk S, Thomas HJ, Lucassen AM, Evans DG, Maher ER,
Maughan T, Dimas A, Dermitzakis E, Cazier JB, Aaltonen LA, Pharoah P,
Kerr DJ, Carvajal-Carmona LG, Campbell H, Dunlop MG, Tomlinson IP
(2010) Meta-analysis of three genome-wide association studies identifies
susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and
20q13.33. Nat Genet 42(11): 973–977.
Huhn S, Bevier M, Pardini B, Naccarati A, Vodickova L, Novotny J,
Vodicka P, Hemminki K, Forsti A (2014) Colorectal cancer risk and
patients’ survival: influence of polymorphisms in genes somatically
mutated in colorectal tumors. Cancer Causes Control 25(6): 759–769.
Ishikawa Y, Ito S, Nagata K, Sakai LY, Bachinger HP (2016) Intracellular
mechanisms of molecular recognition and sorting for transport of large
extracellular matrix molecules. Proc Natl Acad Sci USA 113(41):
E6036–E6044.
Jiao S, Peters U, Berndt S, Brenner H, Butterbach K, Caan BJ, Carlson CS,
Chan AT, Chang-Claude J, Chanock S, Curtis KR, Duggan D, Gong J,
Harrison TA, Hayes RB, Henderson BE, Hoffmeister M, Kolonel LN,
Le Marchand L, Potter JD, Rudolph A, Schoen RE, Seminara D,
Slattery ML, White E, Hsu L (2014) Estimating the heritability of
colorectal cancer. Hum Mol Genet 23(14): 3898–3905.
Johns LE, Houlston RS (2001) A systematic review and meta-analysis of
familial colorectal cancer risk. Am J Gastroenterol 96(10): 2992–3003.
Kemp Z, Carvajal-Carmona L, Spain S, Barclay E, Gorman M, Martin L,
Jaeger E, Brooks N, Bishop DT, Thomas H, Tomlinson I,
Papaemmanuil E, Webb E, Sellick GS, Wood W, Evans G, Lucassen A,
Maher ER, Houlston RS (2006) Evidence for a colorectal cancer
susceptibility locus on chromosome 3q21-q24 from a high-density SNP
genome-wide linkage scan. Hum Mol Genet 15(19): 2903–2910.
Kerber RA, Neklason DW, Samowitz WS, Burt RW (2005) Frequency of
familial colon cancer and hereditary nonpolyposis colorectal cancer
(Lynch syndrome) in a large population database. Fam Cancer 4(3):
239–244.
Khurana E, Fu Y, Colonna V, Mu XJ, Kang HM, Lappalainen T, Sboner A,
Lochovsky L, Chen J, Harmanci A, Das J, Abyzov A, Balasubramanian S,
Beal K, Chakravarty D, Challis D, Chen Y, Clarke D, Clarke L,
Cunningham F, Evani US, Flicek P, Fragoza R, Garrison E, Gibbs R,
Gumus ZH, Herrero J, Kitabayashi N, Kong Y, Lage K, Liluashvili V,
Lipkin SM, MacArthur DG, Marth G, Muzny D, Pers TH, Ritchie GR,
Rosenfeld JA, Sisu C, Wei X, Wilson M, Xue Y, Yu F, Dermitzakis ET,
Yu H, Rubin MA, Tyler-Smith C, Gerstein M (2013) Integrative
annotation of variants from 1092 humans: application to cancer genomics.
Science 342(6154): 1235587.
Kobayashi H, Komatsu S, Ichikawa D, Kawaguchi T, Hirajima S, Miyamae M,
Okajima W, Ohashi T, Kosuga T, Konishi H, Shiozaki A, Fujiwara H,
Okamoto K, Tsuda H, Otsuji E (2015) Overexpression of denticleless E3
ubiquitin protein ligase homolog (DTL) is related to poor outcome in
gastric carcinoma. Oncotarget 6(34): 36615–36624.
Kong A, Cox NJ (1997) Allele-sharing models: LOD scores and accurate
linkage tests. Am J Hum Genet 61(5): 1179–1188.
Lips EH, van Eijk R, de Graaf EJ, Oosting J, de Miranda NF, Karsten T,
van de Velde CJ, Eilers PH, Tollenaar RA, van Wezel T, Morreau H (2008)
Integrating chromosomal aberrations and gene expression profiles to
dissect rectal tumorigenesis. BMC Cancer 8: 314.
Middeldorp A, Jagmohan-Changur SC, van der Klift HM, van Puijenbroek M,
Houwing-Duistermaat JJ, Webb E, Houlston R, Tops C, Vasen HF,
Devilee P, Morreau H, van Wezel T, Wijnen J (2010) Comprehensive
genetic analysis of seven large families with mismatch repair proficient
colorectal cancer. Genes Chromosomes Cancer 49(6): 539–548.
Montazeri Z, Theodoratou E, Nyiraneza C, Timofeeva M, Chen W, Svinti V,
Sivakumaran S, Gresham G, Cubitt L, Carvajal-Carmona L,
Bertagnolli MM, Zauber AG, Tomlinson I, Farrington SM, Dunlop MG,
Campbell H, Little J (2016) Systematic meta-analyses and field synopsis of
genetic association studies in colorectal adenomas. Int J Epidemiol 45(1):
186–205.
Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T,
Graff RE, Holst K, Moller S, Unger RH, McIntosh C, Nuttall E, Brandt I,
Penney KL, Hartman M, Kraft P, Parmigiani G, Christensen K,
Koskenvuo M, Holm NV, Heikkila K, Pukkala E, Skytthe A, Adami HO,
Kaprio J (2016) Familial risk and heritability of cancer among twins in
Nordic countries. JAMA 315(1): 68–76.
Muzny D, Bainbridge M, Chang K, Dinh H, Drummond J, Fowler G, Kovar C,
Lewis L, Morgan M, Newsham I, Reid J, Santibanez J, Shinbrot E,
Trevino L, Wu Y, Wang M, Gunaratne P, Donehower L, Creighton C,
Wheeler D, Gibbs R, Lawrence M, Voet D, Jing R, Cibulskis K,
Sivachenko A, Stojanov P, McKenna A, Lander E, Gabriel S, Getz G,
Ding L, Fulton R, Koboldt D, Wylie T, Walker J, Dooling D, Fulton L,
Delehaunty K, Fronick C, Demeter R, Mardis E, Wilson R, Chu A,
Chun H, Mungall A, Pleasance E, Robertson A, Stoll D, Balasundaram M,
Birol I, Butterfield Y, Chuah E, Coope R, Dhalla N, Guin R, Hirst C,
Hirst M, Holt R, Lee D, Li H, Mayo M, Moore R, Schein J, Slobodan J,
Tam A, Thiessen N, Varhol R, Zeng T, Zhao Y, Jones S, Marra M, Bass A,
Ramos A, Saksena G, Cherniack A, Schumacher S, Tabak B, Carter S,
Pho N, Nguyen H, Onofrio R, Crenshaw A, Ardlie K, Beroukhim R,
Winckler W, Getz G, Meyerson M, Protopopov A, Zhang J,
Hadjipanayis A, Lee E, Xi R, Yang L, Ren X, Zhang H, Sathiamoorthy N,
Shukla S, Chen P, Haseley P, Xiao Y, Lee S, Seidman J, Chin L, Park P,
Kucherlapati R, Auman J, Hoadley K, Du Y, Wilkerson M, Shi Y,
Liquori C, Meng S, Li L, Turman Y, Topal M, Tan D, Waring S, Buda E,
Walsh J, Jones C, Mieczkowski P, Singh D, Wu J, Gulabani A, Dolina P,
Bodenheimer T, Hoyle A, Simons J, Soloway M, Mose L, Jefferys S, Balu S,
O’Connor B, Prins J, Chiang D, Hayes D, Perou C, Hinoue T,
Weisenberger D, Maglinte D, Pan F, Berman B, Van Den Berg D, Shen H,
Triche Jr T, Baylin S, Laird P, Getz G, Noble M, Voet D, Saksena G,
Gehlenborg N, DiCara D, Zhang J, Zhang H, Wu C, Liu S, Shukla S,
Lawrence M, Zhou L, Sivachenko A, Lin P, Stojanov P, Jing R, Park R,
Nazaire M, Robinson J, Thorvaldsdottir H, Mesirov J, Park P, Chin L,
Thorsson V, Reynolds S, Bernard B, Kreisberg R, Lin J, Iype L, Bressler R,
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